Drug Trial Radar · NCT00446056
Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)
Last checked: Nov 19, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Sep 25, 2003
Primary completion
Jun 16, 2004
Study completion Jun 16, 2004
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to \< 15. The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.
Conditions
- Asthma
Interventions
MK0476, montelukast sodium / Duration of Treatment: 4 WeeksDrug
Comparator: ketotifen / Duration of Treatment: 4 WeeksDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement of morning peak expiratory flow over first 2 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.